Could a Lab-Made antibody be the next acne breakthrough?

NCT ID NCT04856917

Completed Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 2 trial tested a drug called imsidolimab (ANB019) in 123 people with moderate to severe acne. The drug is a lab-made antibody designed to reduce inflammation. Researchers measured how much facial acne lesions decreased over 12 weeks compared to a placebo. The goal is to see if this treatment is safe and effective for acne.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: imsidolimab (ANB019), a lab-made antibody
What this could lead to: If it works, this could offer a new treatment option for people with moderate to severe acne who don't respond to current therapies.
What could go wrong: This is an early Phase 2 trial with only 123 participants, so results may not apply to everyone. The drug may not reduce acne better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACNE VULGARIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACNE VULGARIS

Contacts and locations

Locations

Site 10-101

San Antonio, Texas, 78213, United States
Site 10-102

College Station, Texas, 77845, United States
Site 10-103

Austin, Texas, 78759, United States
Site 10-104

Detroit, Michigan, 48202, United States
Site 10-105

Murfreesboro, Tennessee, 37130, United States
Site 10-106

Sherman Oaks, California, 91403, United States
Site 10-107

Tampa, Florida, 33613, United States
Site 10-108

Tampa, Florida, 33607, United States
Site 10-109

New Orleans, Louisiana, 70119, United States
Site 10-110

Portsmouth, New Hampshire, 03801, United States
Site 10-111

Fountain Valley, California, 92708, United States
Site 10-112

New Orleans, Louisiana, 70119, United States
Site 10-113

Sweetwater, Florida, 33172, United States
Site 10-114

Hot Springs, Arkansas, 71913, United States
Site 10-115

Waterloo, Ontario, N2J1C4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.